Evondos closes EUR 20M in new funding, accelerates growth of its medical robots business.

Evondos, a Salo, Finland-based medication robotics company, announced closing in EUR 20M ($24M) in a new investment round.

The money comes from Norwegian investment company Serendipity Partners, which becomes a major owner in the company, with 35% of the shares. In total, Evondos has more than 30 shareholders, most of whom are Finnish private individuals.

The funding will help Evondos to expand in new international markets, strengthen the existing organization and invest significantly in exports.

Evondos, led by CEO Jyrki Niinistö, developed a service that enables patients in need of long-term medical treatment to get the right medication at the right time and in the right dosage – completely automatically. Those medicine dispensing robots provide significant help to home care daily work, both from home care customer’s welfare and from the economic point of view.

The company has about 1000 patients using the device, with users from Norway, Sweden and Denmark.